Mediwound (MDWD) PT Set at $10.00 by Oppenheimer
Mediwound (NASDAQ:MDWD) has been assigned a $10.00 target price by investment analysts at Oppenheimer in a research note issued on Friday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Oppenheimer’s price target would indicate a potential upside of 110.53% from the company’s previous close.
Several other equities research analysts also recently commented on the stock. Jefferies Group set a $10.00 target price on shares of Mediwound and gave the company a “buy” rating in a research note on Friday, August 25th. SunTrust Banks set a $9.00 target price on shares of Mediwound and gave the stock a “buy” rating in a report on Thursday, November 16th. Zacks Investment Research lowered shares of Mediwound from a “buy” rating to a “hold” rating in a research report on Tuesday, November 21st. ValuEngine raised shares of Mediwound from a “strong sell” rating to a “sell” rating in a research report on Saturday, November 25th. Finally, Cowen started coverage on shares of Mediwound in a research report on Thursday, September 28th. They issued an “outperform” rating and a $9.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company’s stock. Mediwound presently has an average rating of “Buy” and a consensus target price of $9.13.
Mediwound (NASDAQ MDWD) traded up $0.15 during trading hours on Friday, reaching $4.75. 50,100 shares of the company’s stock were exchanged, compared to its average volume of 39,795. Mediwound has a 52-week low of $4.15 and a 52-week high of $8.25.
A number of large investors have recently added to or reduced their stakes in MDWD. Migdal Insurance & Financial Holdings Ltd. grew its stake in Mediwound by 9.5% during the third quarter. Migdal Insurance & Financial Holdings Ltd. now owns 2,220,972 shares of the biopharmaceutical company’s stock worth $11,882,000 after buying an additional 192,860 shares in the last quarter. Alyeska Investment Group L.P. acquired a new stake in Mediwound during the third quarter worth about $2,140,000. Nationwide Fund Advisors acquired a new stake in Mediwound during the third quarter worth about $1,538,000. Renaissance Technologies LLC grew its stake in Mediwound by 1.7% during the first quarter. Renaissance Technologies LLC now owns 75,600 shares of the biopharmaceutical company’s stock worth $499,000 after buying an additional 1,300 shares in the last quarter. Finally, Wells Fargo & Company MN grew its stake in Mediwound by 23.5% during the second quarter. Wells Fargo & Company MN now owns 65,763 shares of the biopharmaceutical company’s stock worth $447,000 after buying an additional 12,522 shares in the last quarter. 29.46% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: This news story was posted by Watch List News and is the property of of Watch List News. If you are accessing this news story on another website, it was stolen and republished in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.watchlistnews.com/mediwound-mdwd-pt-set-at-10-00-by-oppenheimer/1751623.html.
MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.
Receive News & Ratings for Mediwound Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound Ltd and related companies with Analyst Ratings Network's FREE daily email newsletter.